Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from BioNTech SE ( (BNTX) ).
On June 2, 2025, BioNTech SE entered into a Global Co-Development and Co-Commercialization Agreement with Bristol-Myers Squibb Company to develop, manufacture, and commercialize the bispecific antibody BNT327 for various solid tumor types. The agreement, which was amended on August 15, 2025, includes a $1.5 billion upfront payment to BioNTech and up to $7.6 billion in additional milestone payments. The collaboration will see both companies sharing profits and losses equally, with a focus on maximizing the success and efficiency of BNT327’s development and commercialization. This strategic partnership is expected to enhance BioNTech’s position in the oncology market and provide significant financial benefits.
The most recent analyst rating on (BNTX) stock is a Buy with a $136.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.
Spark’s Take on BNTX Stock
According to Spark, TipRanks’ AI Analyst, BNTX is a Neutral.
BioNTech SE’s overall stock score is driven by its strong balance sheet and positive earnings call sentiment, despite profitability and cash flow challenges. Technical indicators show a positive short-term trend, but valuation is impacted by negative earnings. Strategic collaborations and a strong cash position provide a positive outlook, but operational improvements are necessary for long-term stability.
To see Spark’s full report on BNTX stock, click here.
More about BioNTech SE
BioNTech SE is a biotechnology company based in Mainz, Germany, primarily focused on developing and manufacturing immunotherapies for cancer and other serious diseases. The company is known for its work in developing mRNA-based vaccines and therapeutics, and it has a significant presence in the global pharmaceutical market.
Average Trading Volume: 735,145
Technical Sentiment Signal: Buy
Current Market Cap: $27.04B
Find detailed analytics on BNTX stock on TipRanks’ Stock Analysis page.